Bristol-Myers Squibb Enhances Co-pay Assistance Program for Entecavir (Baraclude) for Hepatitis B

Bristol-Myers Squibb this summer expanded its co-pay benefit program for individuals receiving or wishing to use entecavir (Baraclude) who have private insurance policies with out-of-pocket costs. The enhanced program will save eligible patients up to $200 per month for 4 years. Eligible participants may request a Co-Pay Benefit Card from their healthcare providers.